Skip to main content
. 2022 Jan 19;332:111199. doi: 10.1016/j.forsciint.2022.111199

Table 2.

Detailed Information Regarding All Cases.

 Demographics of Coronial Post-Vaccination Deaths
 Results of Ancillary Investigations Performed
Case No. Age Gender Vaccine Dose Number of days post-vaccination Autopsy Cause of Death Signs of Anaphylaxisa Total Tryptase (ug/l) IgE (IU/mL) CRP (mg/L) Histological Featuresb
1 86 Female Pfizer-BioNTech 1 2 Yes Spontaneous acute right intracerebral hemorrhage No 5.3 N.A.c 197 No
2 67 Male Pfizer-BioNTech 1 2 Yes Sigmoid volvulus No 4.4 N.A.c 28.8 No
3 74 Male Pfizer-BioNTech 1 0 Yes Coronary artery disease No 18.7 28.8 1.9 No
4 86 Male Pfizer-BioNTech 1 2 Yes Bleeding duodenal ulcer No 5.8 129 18.4 No
5 63 Male Pfizer-BioNTech 2 1 Yes Ischemic heart disease No 20.2 2529 1 No
6 67 Male Pfizer-BioNTech 2 3 Yes Hypertensive and ischemic heart disease No 18.9 23.9 3.9 No
7 76 Male Pfizer-BioNTech 2 2 Yes Ischemic heart disease No 102 27.5 21.2 No
8 91 Male Pfizer-BioNTech 2 1 Yes Ruptured acute myocardial infarction No 6.1 311 89.8 No
9 76 Female Pfizer-BioNTech 2 1 Yes Subarachnoid hemorrhage due to ruptured berry aneurysm No 20.1 62.9 7 No
10 80 Male Pfizer-BioNTech 1 0 Yes Ischemic heart disease No 8.1 4405 1.7 No
11 86 Male Pfizer-BioNTech 2 1 Yes Ischemic heart disease No 6.2 1 4.8 No
12 94 Female Pfizer-BioNTech 2 1 Yes Hypertensive heart disease No 14.9 113 1 No
13 69 Male Pfizer-BioNTech 2 0 Yes Ischemic heart disease No 17.7 502 0.3 No
14d 72 Male Pfizer-BioNTech 1 0 No Pneumonia – – – – –
15 63 Male Pfizer-BioNTech 2 0 Yes Ruptured ascending aortic dissection No 9.2 245 0.6 No
16 53 Male Pfizer-BioNTech 1 1 Yes Acute right coronary thrombosis No 7.4 Rejected Rejected Yes
17 69 Male Pfizer-BioNTech 2 0 Yes Severe interstitial lung disease with coronary artery disease No 4.8 17.8 19 No
18d 72 Female Pfizer-BioNTech 2 1 No 1a) Sepsis from pneumonia and UTI b) Acute myocardial infarction – – – – –
19 23 Male Pfizer-BioNTech 2 1 Yes Severe obesity, with associated cardiomyopathy, hypoventilation syndrome and obstructive sleep apnea No > 200 594 16.8 No
20 80 Male Pfizer-BioNTech 1 3 No Coronary artery disease with chronic obstructive pulmonary disease – – – – –
21d 65 Male Moderna 2 1 Yes Head injury No 39.2 173 28.1 No
22d 56 Male Moderna 2 1 Yes Cerebral infarction with hemorrhage No > 200 35.3 Rejected No
23 52 Male Pfizer-BioNTech 1 1 Yes Coronary artery disease No 28.8 9.6 5.5 No
24 53 Male Moderna 2 2 Yes Right coronary artery anomalous origin with atherosclerotic ostial stenosis No 9.1 279 17.3 No
25 51 Male Moderna 2 3 Yes Coronary artery disease No 20.4 19.8 5.9 No
26 53 Female Pfizer-BioNTech 2 1 Yes Coronary atherosclerosis No 8.4 42.5 10.1 No
27d 33 Male Moderna 2 1 Yes Consistent with multi organ failure following cardiac arrest due to right ventricular dysplasia No 10.3 243 155 No
28 39 Male Pfizer-BioNTech 1 0 Yes Ischemic heart disease No 43.4 513 2.4 No
29 72 Female Pfizer-BioNTech 1 2 Yes Ischemic heart disease No 44.5 6.3 0.5 No
20 60 Male Pfizer-BioNTech 1 2 Yes Ischemic heart disease No 9.7 24 2.3 No
31 96 Female Pfizer-BioNTech 2 2 No Coronary artery disease – – – – –
32 86 Male Pfizer-BioNTech 1 0 No Hypertensive heart disease – – – – –
33 67 Male Pfizer-BioNTech 2 1 Yes Head injury No 52 59.3 3.2 No

Table 2 lists the details of all 33 cases of this study, comprising 28 who had undergone an autopsy and 5 cases who were not subjected to an autopsy. The majority (84.8%) of the cases received the Pfizer-BioNTech vaccine as this was the first and initially only vaccine available in Singapore at the time. No signs of anaphylaxis or histological features suggesting anaphylaxis, myocarditis and thrombosis were present in all cases who underwent an autopsy. Serum total tryptase was greater than 43 in 6 cases.

a

Refers to signs such as facial (including periorbital, lips etc.) or airway edema, skin changes (e.g. rash, urticaria)

b

Refers to the presence of eosinophilic infiltration, the presence of myocarditis and/or thrombosis

c

Not part of initial sampling protocol

d

Cases who sustained neurological or cardiovascular compromise requiring medical resuscitation within 72 h of receiving the vaccine and subsequently demised after a period of hospitalization